Purchase this article with an account.
Lea Querques, Maria Cristina Parravano, Riccardo Sacconi, Alessandro Rabiolo, Maria Vittoria Cicinelli, Adriano Carnevali, Luigi De Vitis, Giorgia Albertini, Francesco Bandello, Giuseppe Querques; Ischemic index changes in diabetic retinopathy after intravitreal dexamethasone implant using ultra wide-field fluorescein angiography: a pilot study. Invest. Ophthalmol. Vis. Sci. 2017;58(8):923.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the effect dexamethasone intravitreal implant on peripheral ischemia in patients affected by diabetic macular edema (DME).
Patients with treatment naïve diabetic retinopathy undergoing intravitreal dexamethasone implant for diabetic macular edema (DME) between October 2015 and July 2016. Patients underwent a comprehensive ocular examination at baseline (< 2 weeks before treatment) and 10 ± 2 weeks after dexamethasone implant including best corrected visual acuity (BCVA), intraocular pressure (IOP), optical coherence tomography (OCT), ultra-widefield (UWF) retinography and UWF fluorescein angiography.
Five eyes of three consecutive patients (all males; mean age 73.3 ± 10.1 years) with type 2 DM were enrolled. Mean duration of DR was 6.9 ± 3.9 years. Mean interval between UWFA acquisition was 12.1 ± 2.1 weeks and the mean interval between intravitreal injection and UWFA acquisition was 11.0 ± 1.6 weeks. Mean pre- and post-injection BCVA was 0.37 ± 0.21 logMAR and 0.29 ± 0.09 logMAR, respectively. Mean pre- and post-injection CMT was 457.8 ± 123.4 μm and 388.4 ± 50.3 μm, respectively. Mean pre- and post-injection ISI was 37.5 ± 26.2 % and 16.9 ± 12.2 % (2.2 folds reduction), respectively.
Intravitreal dexamethasone implant reduces peripheral retina ischemia in patients with DR.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only